Astria Therapeutics, Inc. (ATXS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-01-23

Key Insights

Astria Therapeutics was acquired by BioCryst Pharmaceuticals through a merger transaction, with Astria becoming a wholly-owned subsidiary of BioCryst.
The merger was financed in part by a $400 million term loan agreement entered into by BioCryst, with Astria as a guarantor.
As a result of the merger, Astria's common stock will be delisted from the Nasdaq and its reporting obligations under the Exchange Act will be terminated.

Want the newest filings?

This analysis covers the filing from 2026-01-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-21

Astria Therapeutics, Inc. has entered into a merger agreement with BioCryst Pharmaceuticals, Inc., which was approved by the majority of Astria's shareholders in a special meeting.
The merger-related compensation for Astria's named executive officers was also approved by shareholders in a non-binding advisory vote.
Since the merger proposal was approved, the proposed adjournment of the special meeting was rendered moot and not called for a vote.

Other reports for Astria Therapeutics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.